Emerald Clinics sees potential in filling evidence gap for cannabinoid products
Emerald operates a network of clinics specialised in assessing the safety and efficacy of unregistered medicines including cannabinoid medicines.
Company
Gold Anti Trust Action Committee
.:[TICKER]
The Gold Anti-Trust Action Committee was organized in the fall of 1998 to expose, oppose, and litigate against collusion to control the price and supply of gold and related financial instruments. The committee arose from essays by Bill Murphy, a financial commentator on the Internet (LeMetropoleCafe.com), and by Chris Powell, a newspaper editor in Connecticut. Murphy's essays reported evidence of collusion among financial institutions to suppress the price of gold. Powell, whose newspaper had been involved in antitrust litigation, replied with an essay proposing that gold mining and investor interests should act on Murphy's essays by bringing antitrust lawsuits against financial institutions involved in the collusion against gold.
170 stories · page 9 of 9
Emerald Clinics lists on the ASX, plans to expand clinics across Australia and the UK
The company specialises in the appropriate use of unregistered medicines, including cannabinoid treatments, and the creation of robust and ethically sourced real-world clinical evidence.
Tesoro Resources spins drill bit for gold in Chile after ASX re-listing
The company is drilling at the El Zorro Gold Project to extend the mineralised zone at Coquetas which has previously reported multiple, wide, high-grade gold intersections.
Orthocell grabs Japanese patent protection for tissue repair rope CelGro
The collagen ropes enhance soft tissue repairs to areas such as anterior cruciate ligaments or ACLs.
Investments and investor services
Cobalt set for bearish 2019 but demand fundamentals remain strong
Despite a sharp price correction in 2018, shrinking supply sources and growing demand for battery chemicals are predicted to sustain cobalt prices into the 2020s.
Investments and investor services
Vanadium prices remain strong into 2019 as further new energy applications are developed
Despite its enormous potential as a new energy mineral, steel remains the primary price driver for vanadium.
Investments and investor services
Base metals perform poorly in 2018 with analysts expecting ‘heightened volatility’ in 2019
Price corrections were the norm for base metals in 2018 and ongoing uncertainty around trade has offset price upside from declining supply and stronger demand.
Oil supply reductions to potentially push up crude prices amid fundamental sector challenges
The oil industry faces political and financial uncertainty as global production is curtailed to prop up the volatile price of crude.
Lithium outlook uncertain amid growing demand, oversupply and potential disruptive technologies
The lithium price faces a slow downward trend to 2022 as the market shifts into a supply surplus in 2019.
Investments and investor services
Forecast copper supply constraints provide optimism despite 2018 price decline
Sustained demand growth and forecast supply cuts have not yet translated into higher copper prices as the Chinese economy slows.